Yes it seems MXC @ $140MILL & CPH $210MILL are better investment opportunities than Medlab's cannabis phase 3 trial @$70mill. Nothing exciting here for Medlab's cannabis offering compared to other cannabis stocks in the world at present. @$70mill value it assumes Medlab has nothing special to offer and its trials are not world standard like the others mentioned above. So perhaps fair value for Medlab's phase 3 is in the range of $40mill-$70mill range until the world wakes up. Until then investment interest is shying away from Medlab as evident in the past few months sell down from 0.40c to today's 0.20c. A whopping 50% decrease is shareholder value in a matter of months. While the other cannabis stocks climb to new heights with better trials and product offerings. One can only compare market caps to determine which company is a better investment.
If Medlab's current cannabis trial work was on LSE or Nasdaq would it be higher than current AUS$ value?
- Forums
- ASX - By Stock
- MDC
- Ann: Reminder of Investor Webinar - NanaBis Phase III Trial
Ann: Reminder of Investor Webinar - NanaBis Phase III Trial, page-8
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MDC (ASX) to my watchlist
|
|||||
Last
$6.60 |
Change
0.000(0.00%) |
Mkt cap ! $15.07M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
MDC (ASX) Chart |
Day chart unavailable